Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Shea Deklotz

Physician Assistant, Surgical Portland, OR Physician Assistant

NPI 1679819239 CMS profile 10605460

3303 S Bond Ave, Portland, OR 97239

Open in the dashboard

General payments

$4,741

294 records reported · program years 2021–2025

Research payments

$280

Paid to them · 1 record reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shea Deklotz of Portland, OR is reported in the CMS Open Payments database as having received $4,741 across 294 general payments and $280 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Physician Assistant, Surgical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $270 12
2024 General $1,091 69
2023 General $1,107 80
2022 General $954 55
2021 General $1,319 78
2021 Research $280 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shea Deklotz
  • Physician Assistant, Surgical median
  • Middle half of Physician Assistant, Surgical
  • National median

In program year 2025, general payments to Shea Deklotz were reported at $270. Among 8,152 Physician Assistant, Surgical profiles paid that year, the median was $146 and the middle half received between $51 and $385.

Show as a table
Year Shea Deklotz Physician Assistant, Surgical median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,319 $111 $36–$285 $132
2022 $954 $126 $44–$350 $149
2023 $1,107 $137 $47–$355 $160
2024 $1,091 $146 $49–$384 $164
2025 $270 $146 $51–$385 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $952 81 payments
  2. Collegium Pharmaceutical, Inc. $940 83 payments
  3. Medtronic, Inc. $710 23 payments
  4. Pfizer Inc. $348 18 payments
  5. Lilly USA, LLC $259 13 payments
  6. Lundbeck LLC $163 7 payments
  7. Amgen Inc. $161 9 payments
  8. Vanda Pharmaceuticals Inc. $115 5 payments
  9. TerSera Therapeutics LLC $112 5 payments
  10. Biohaven Pharmaceuticals, Inc. $83 5 payments
  11. Other $900 45 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,741 294 payments
Products named General payments · program years 2021–2025
  1. QULIPTA $465 47 payments
  2. UBRELVY $457 45 payments
  3. XTAMPZA $450 35 payments
  4. BELBUCA $363 37 payments
  5. INTELLIS ADAPTIVESTIM $279 3 payments
  6. NURTEC ODT $265 14 payments
  7. EMGALITY $259 13 payments
  8. REYVOW $244 12 payments
  9. AIMOVIG $221 13 payments
  10. SYNCHROMEDII $199 10 payments
  11. Other $2,557 126 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2021–2025
  1. Medtronic, Inc. $280 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 44 drugs

Part D claims

3,760

Median for Physician Assistant: 241

Drug cost

$196,468

Median for Physician Assistant: $4,110

Branded share of claims

22.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nurtec Odt Rimegepant Sulfate Brand 27 $43,804
Oxycontin Oxycodone Hcl Brand 42 $23,195
Ubrelvy Ubrogepant Brand 14 $19,055
Oxycodone Hcl Generic 721 $15,372
Aimovig Autoinjector Erenumab-Aooe Brand 11 $14,866
Movantik Naloxegol Oxalate Brand 12 $9,894
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 283 $8,682
Morphine Sulfate Er Morphine Sulfate Brand 187 $8,675
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 210 $5,926
Hydromorphone Hcl Generic 305 $5,761

The 10 drugs with the highest cost, of 44 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BELBUCA
  • Collegium Pharmaceutical, Inc. $106
$106 — —
XTAMPZA
  • Collegium Pharmaceutical, Inc. $90
$90 — —
QULIPTA
  • AbbVie, Inc. $82
$82 — —
BOTOX
  • AbbVie, Inc. $76
$76 — —
UBRELVY
  • AbbVie, Inc. $53
$53 14 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

295 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record